|Year : 2019 | Volume
| Issue : 1 | Page : 23-28
Effects of Magnesium Replacement Therapy in Patients with Chronic Stable Heart Failure and Normal Magnesium Level
Ahmad Amin1, Mitra Chitsazan1, Mandana Chitsazan2, Arezoo Haghighattalab1, Sepideh Taghavi1, Nasim Naderi1
1 Department of Heart Failure and Transplantation, Rajaei Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
2 Cardiology Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran
|Date of Web Publication||23-Apr-2019|
Dr. Mitra Chitsazan
Vali-Asr Ave., Niyayesh Blvd., Rajaei Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran
Source of Support: None, Conflict of Interest: None
Objectives: In the present study, we sought to assess the changes in functional, biochemical, and echocardiographic measurements of heart failure (HF) during a 12-week Mg2+ supplementation in chronic stable HF patients. Methods: Twenty patients with clinically stable New York Heart Association (NYHA) Class I–III systolic HF (echocardiography-derived left ventricular ejection fraction [LVEF] of <40%) and normal magnesium level (1.5–2 mg/dl) were recruited consecutively in this before and after study. The patients received oral Mg2+ (400 mg MgO b.i.d., for a total of 482.6 mg of elemental Mg2+) for a total of 12 weeks. Results: Twenty patients, including 10 (50%) men, with a mean ± standard deviation age of 53 ± 15 years were included. The 6-min walk distance significantly increased from 379 (348–440) m to 583 (506–604) m. High-sensitivity C-reactive protein significantly decreased from 12 (7–14) to 3 (2–4) mg/dL (P < 0.001). N-terminal pro-brain natriuretic peptide also declined from 653 (415–2660.75) to 189.5 (82.5–537.75) ng/dL (P < 0.001). The LVEF and systolic pulmonary artery pressure significantly improved (both P < 0.001). Conclusion: We demonstrated beneficial effects of Mg2+ supplementation in patients with normal magnesium level. We suggest routine Mg2+ supplementation to all HF patients with low-to-normal Mg2+ levels and normal kidney function.
Keywords: Heart failure, magnesium, pro-brain natriuretic peptide
|How to cite this article:|
Amin A, Chitsazan M, Chitsazan M, Haghighattalab A, Taghavi S, Naderi N. Effects of Magnesium Replacement Therapy in Patients with Chronic Stable Heart Failure and Normal Magnesium Level. Res Cardiovasc Med 2019;8:23-8
|How to cite this URL:|
Amin A, Chitsazan M, Chitsazan M, Haghighattalab A, Taghavi S, Naderi N. Effects of Magnesium Replacement Therapy in Patients with Chronic Stable Heart Failure and Normal Magnesium Level. Res Cardiovasc Med [serial online] 2019 [cited 2020 Jan 27];8:23-8. Available from: http://www.rcvmonline.com/text.asp?2019/8/1/23/256878
| Introduction|| |
A growing body of literature shows the prevalence and significance of altered magnesium metabolism in congestive heart failure (HF). A considerable number of studies have documented lower extracellular and intracellular Mg2+ levels in patients with HF compared with healthy controls.,,,, Hypomagnesemia has been found to be associated with higher mortality in HF patients. Increased mortality in HF patients with hypomagnesemia is believed to be related to the development of life-threatening ventricular arrhythmias rather than clinical and hemodynamic compromise. However, recent studies suggest that the beneficial role of Mg2+ supplementation in cardiovascular diseases is beyond its antiarrhythmic role. Mg2+ therapy has been shown to be associated with improved endothelial function and exercise tolerance in patients with coronary artery disease., The beneficial effects of multiple micronutrient supplementations including Mg2+ in HF patients have been shown previously.
However, still, data are lacking regarding the effects of Mg2+ supplementation in HF patients with normal magnesium level. As a result, in the present study, we sought to assess the changes in functional, biochemical, and echocardiographic measurements of HF during a 12-week Mg2+ supplementation in chronic stable HF patients.
| Methods|| |
Study design and population
Twenty patients with clinically stable New York Heart Association (NYHA) Class I–III systolic HF (echocardiography-derived left ventricular ejection fraction [LVEF] of <40%) and normal magnesium level (1.5–2 mg/dl) were recruited consecutively from the Heart Failure and Transplant Clinic of Rajaei Cardiovascular, Medical and Research Center, Tehran, Iran, from June 2017 to September 2017. Patients with a history of chronic kidney disease, cirrhosis, peripheral vascular diseases, pregnancy, chronic diarrhea, inflammatory bowel disease, malabsorption disorders, and arrhythmias were excluded. Patients were also excluded if they were taking Mg2+ supplements, steroids, and nonsteroidal anti-inflammatory drugs. Patients had been receiving optimized anti-HF therapy [adequate doses of diuretics and neurohormonal blockades including beta-blockers and angiotensin-converting enzyme inhibitors (or angiotensin receptor blockers) and aldosterone antagonists] according to the latest guidelines on HF,, and none of them had been hospitalized, had emergency visits, or changed medical therapy during the 3 preceding months. Moreover, patients were kept on the same medical regimen (including the type and dose of the medications) during all the study period.
The study was designed as an interventional before and after study. At study entry, the subjects' clinical history was reviewed, and physical examination, echocardiography, 6-min walk test (6MWT), and biochemical measurements were performed. In addition to their background therapy for HF, patients received oral Mg2+ (400 mg MgO b.i.d., for a total of 482.6 mg of elemental Mg2+). Patients were visited every 2 weeks, and drug toleration as well as probable side effects was evaluated. At the end of the 12th week, all patients were reevaluated by the same investigators with examining biomedical indices, exercise parameters, and echocardiographic assessment.
The present study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki. Institutional Review Boards at Rajaei Cardiovascular, Medical and Research Center approved the study protocol, and written informed consent was obtained from all patients.
Assessment of exercise capacity
NYHA functional class of patients was assessed by the same investigator evaluating patients at rest, dressing, walking, and climbing the stairs. NYHA Classes range from I (no symptoms) to IV (symptoms at rest). Functional capacity of patients was also assessed using the 6MWT, conducted in a flat straight 30 m corridor according to the latest guideline provided by the American Thoracic Society. The distance walked in 6 min is expressed in meters.
Blood sampling and analysis
Basal blood samples were taken at 08:00 h from an antecubital vein after a 30-min rest in supine position. Blood samples were collected in the morning after an overnight fast and immediately processed on the same day. Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were measured using the ELISA method (BioMedia-Corp, Bratislava-Slovakia). Serum magnesium level was measured using colorimetric method. Normal magnesium level was defined as 1.5–2 mEq/L.
All patients underwent a complete echocardiographic examination with a commercially available system (Vivid™ 7, GE Healthcare, Horten, Norway). The LV end-systolic and end-diastolic volume and LVEF were measured by the modified biplane Simpson's method from the apical four-and two-chamber views. M-mode LV dimensions were obtained from the parasternal long-axis view. All measurements were averaged over three consecutive beats.
All analyses were conducted by Statistical Package for the Social Sciences software, version 19 (SPSS Inc., Chicago, IL, USA). All data initially were analyzed using the Kolmogorov-Smirnov test to assess for normality. Categorical variables are presented as numbers and percentages and quantitative ones as means ± standard deviation (SD). Categorical data were compared by the Chi-square test; quantitative variables by the Student's t- test, the Mann-Whitney U-test, and the Kruskal–Wallis test, as appropriate. All P values were two-tailed, and P < 0.05 was considered statistically significant.
| Results|| |
Twenty patients with ischemic (n = 4 [20%]) and idiopathic dilated cardiomyopathy (n = 16 [80%]) including 10 (50%) males and 10 (50%) females with a mean ± SD age of 53 ± 15 (range 20–85) were included. Baseline patient characteristics are depicted in [Table 1].
Mg2+ serum level increased from 1.63 ± 0.27 to 2.90 ± 0.17 mEq/L (P < 0.001).
Effects of magnesium on exercise tolerance
The NYHA class significantly improved (P < 0.001). Four patients (20%) improved from NYHA Class III to NYHA Class II. Four patients (20%) improved from NYHA Class III to NYHA Class I. Nine patients (45%) improved from NYHA Class II to NYHA Class I. One patient (5%) deteriorated from NYHA Class III to Class IV. Two patients (10%) remained in their previous NYHA Class (Class II).
The 6-min walk distance (6MWD) significantly increased from 379 (348–440) to 583 (506–604) m [Figure 1].
|Figure 1: Change in 6MWD. (a) Distribution of 6MWD before Mg2+ replacement. (b) Distribution of 6MWD after Mg2+ replacement. 6MWD: 6-min walk distance|
Click here to view
Effects of magnesium on laboratory measurements
High-sensitivity C-reactive protein (Hs-CRP) significantly decreased from 12 (7–14) to 3 (2–4) mg/dL (P < 0.001) [Figure 2]. NT-proBNP also declined from 653 (415–2660.75) to 189.5 (82.5–537.75) ng/dL (P < 0.001) [Figure 3].
|Figure 2: Change in hs-CRP. (a) Distribution of hs-CRP before Mg2+ replacement. (b) Distribution of hs-CRP after Mg2+ replacement. Hs-CRP: High-sensitivity C-reactive protein|
Click here to view
|Figure 3: Change in NT-proBNP. (a) Distribution of NT-proBNP before Mg2+ replacement. (b) Distribution of NT-proBNP after Mg2+ replacement. NT-proBNP: N-terminal pro-brain natriuretic peptide|
Click here to view
Effects of magnesium on echocardiography parameters
The changes in the assessed echocardiographic parameters are provided in [Table 2]. The LVEF [Figure 4] and systolic pulmonary artery pressure (SPAP) significantly improved (both P < 0.001).
|Figure 4: Change in LVEF. (a) Distribution of LVEF before Mg2+ replacement. (b) Distribution of LVEF after Mg2+ replacement. LVEF: Left ventricular ejection fraction|
Click here to view
| Discussion|| |
In the present study, we assessed the beneficial role of long-term Mg2+ supplementation, if any, in HF patients with normal magnesium level. The main finding of our study was that a 12-week trial of Mg2+ therapy in these patients seems to improve exercise capacity, as reflected by 6MWD. It decreases NT-proBNP level in clinically stable HF patients with optimal antifailure medications. Mg2+ supplementation is associated with a significant improvement in LVEF and SPAP. Mg2+ was well tolerated and there were no serious side effects attributable to Mg2+ being seen.
Previous studies suggest that mechanisms such as chronic or aggressive thiazide and loop diuretic therapy; activation of the renin-angiotensin-aldosterone axis; decreased oral intake; “dilutional” reduction in extracellular concentration; chronic hypokalemia; and chronic digitalis therapy are probable etiologies of hypomagnesemia in HF patients.,,,,,,,,,, However, it was shown that Mg2+ intake is below the Recommended Dietary Allowance (RDA) and/or Dietary Reference Intakes (DRI) both in HF patients and healthy controls. Gorelik et al. found no significant difference in the dietary intake of Mg between HF patients and controls.
The majority of the previous research regarding the role of magnesium in chronic HF has been evaluated the association between hypomagnesemia and occurrence of significant life-threatening ventricular arrhythmias and sudden death.,
Hypomagnesemia has been found to be associated with higher mortality in HF patients. Adamopoulos et al. in a propensity-matched population of ambulatory chronic HF patients showed that serum magnesium level of 2 mEq/L or less was associated with increased cardiovascular mortality but not with increased cardiovascular hospitalization. They concluded that this might be explained by the fact that most of these deaths were likely sudden in nature. They linked this increased rate of cardiovascular deaths to the life-threatening ventricular arrhythmias. However, there is no general consensus in the previous literature regarding the role of hypomagnesemia in increasing the mortality in HF patients. Eichhorn et al. in patients with mild-to-moderate HF demonstrated that serum magnesium level does not appear to be an independent risk factor for sudden death or death due to all causes.
Fuentes et al. evaluated effects of acute and chronic oral magnesium supplementation on endothelial function, exercise capacity, and quality of life in 22 patients with symptomatic HF. They found no significant differences between the treatment and placebo arms with respect to daily Mg2+ intake, Minnesota Living with HF questionnaire score, 6-min walk, Mg2+ level, or hemodynamic parameters from baseline at 1 week or 3 months. However, they showed that the small artery elasticity decreased in patients who did not take Mg2+, whereas there it significantly improved in patients receiving Mg2+ supplementations.
Witte et al. showed that long-term multiple micronutrient supplementation (including calcium, magnesium, zinc, copper, selenium, Vitamin A, thiamine, riboflavin, Vitamin B6, folate, Vitamin B12, Vitamin C, Vitamin E, Vitamin D, and coenzyme Q10) can improve LV volumes, LVEF, and quality of life scores in elderly patients with systolic HF.
In accordance with our findings, Almoznino-Sarafian et al. showed that oral Mg2+ supplementation to HF patients significantly attenuates blood levels of CRP concomitantly with a significant elevation of intracellular Mg level. Moreover, data from the National Health and Nutrition Examination Survey 1999–2000 suggests that cardiovascular patients receiving regular and prolonged Mg2+ supplementation are likely to have lower CRP levels.
Whatever the cause, both hypomagnesemia and intracellular magnesium depletion are common electrolyte abnormalities in HF patients. The importance of this electrolyte derangement and replacement strategy in patients with low to low-normal values remains controversial.
As a before and after study in a small number of HF patients, the main limitations of our study are the limited sample size and also the lack of a placebo arm. We attributed all changes seen in biochemical and echocardiographic parameters to magnesium replacement, while these might be affected by a variety of confounders which are only amenable to be assessed through comparisons by a well-matched placebo arm. Definitely, the results provided by a larger group of HF patients in a randomized, double-blind, placebo-controlled study would be more reliable to ascertain the beneficial role of long-term magnesium therapy in HF patients. Despite inherent limitations of such study design, this study provided additional evidence on the beneficial role of magnesium supplementation in clinically stable HF patients with normal magnesium level. To further elucidate the potential of magnesium therapy to be an adjuvant therapy in HF patients, future well-designed randomized, double-blind, placebo-controlled trials with larger sample sizes are suggested.
| Conclusion|| |
We demonstrated that Mg2+ supplementation in patients with normal magnesium level for 12 weeks is associated with significant improvement in LV systolic function, NT-proBNP and hs-CRP serum levels, and exercise tolerance, suggesting potential mechanisms by which Mg2+ could safely benefit chronic stable HF patients with normal magnesium level receiving optimal antifailure medications. We suggest routine Mg2+ supplementation to all HF patients with low-to-normal Mg2+ levels and normal kidney function.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Schwinger RH, Erdmann E. Heart failure and electrolyte disturbances. Methods Find Exp Clin Pharmacol 1992;14:315-25.
Sueta CA, Patterson JH, Adams KF Jr. Antiarrhythmic action of pharmacological administration of magnesium in heart failure: A critical review of new data. Magnes Res 1995;8:389-401.
Wester PO. Electrolyte balance in heart failure and the role for magnesium ions. Am J Cardiol 1992;70:44C-9C.
Douban S, Brodsky MA, Whang DD, Whang R. Significance of magnesium in congestive heart failure. Am Heart J 1996;132:664-71.
Ng LL, Garrido MC, Davies JE, Brochwicz-Lewinski MJ, Tan LB. Intracellular free magnesium in lymphocytes from patients with congestive cardiac failure treated with loop diuretics with and without amiloride. Br J Clin Pharmacol 1992;33:329-32.
Shechter M, Bairey Merz CN, Stuehlinger HG, Slany J, Pachinger O, Rabinowitz B, et al.
Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol 2003;91:517-21.
Shechter M, Sharir M, Labrador MJ, Forrester J, Silver B, Bairey Merz CN, et al.
Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000;102:2353-8.
Witte KK, Nikitin NP, Parker AC, von Haehling S, Volk HD, Anker SD, et al.
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 2005;26:2238-44.
Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, et al.
HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:e1-194.
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al.
ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al.
Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79-108.
Cleland JG, Dargie HJ, Ball SG, Gillen G, Hodsman GP, Morton JJ, et al.
Effects of enalapril in heart failure: A double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985;54:305-12.
Abraham AS, Meshulam Z, Rosenmann D, Eylath U. Influence of chronic diuretic therapy on serum, lymphocyte and erythrocyte potassium, magnesium and calcium concentrations. Cardiology 1988;75:17-23.
Seelig M. Cardiovascular consequences of magnesium deficiency and loss: Pathogenesis, prevalence and manifestations – Magnesium and chloride loss in refractory potassium repletion. Am J Cardiol 1989;63:4G-21G.
O'Keeffe S, Grimes H, Finn J, McMurrough P, Daly K. Effect of captopril therapy on lymphocyte potassium and magnesium concentrations in patients with congestive heart failure. Cardiology 1992;80:100-5.
Dyckner T. Relation of cardiovascular disease to potassium and magnesium deficiencies. Am J Cardiol 1990;65:44K-6K.
Massry SG, Coburn JW, Chapman LW, Kleeman CR. Effect of NaCl infusion on urinary Ca++ and Mg++ during reduction in their filtered loads. Am J Physiol 1967;213:1218-24.
Lemann J Jr., Piering WF, Lennon EJ. Studies of the acute effects of aldosterone and cortisol on the interrelationship between renal sodium, calcium and magnesium excretion in normal man. Nephron 1970;7:117-30.
Lim P, Jacob E. Magnesium deficiency in patients on long-term diuretic therapy for heart failure. Br Med J 1972;3:620-2.
Dørup I, Skajaa K, Clausen T, Kjeldsen K. Reduced concentrations of potassium, magnesium, and sodium-potassium pumps in human skeletal muscle during treatment with diuretics. Br Med J (Clin Res Ed) 1988;296:455-8.
Whang R, Oei TO, Watanabe A. Frequency of hypomagnesemia in hospitalized patients receiving digitalis. Arch Intern Med 1985;145:655-6.
Stevenson RN, Keywood C, Amadi AA, Davies JR, Patterson DL. Angiotensin converting enzyme inhibitors and magnesium conservation in patients with congestive cardiac failure. Br Heart J 1991;66:19-21.
Costello RB, Moser-Veillon PB, DiBianco R. Magnesium supplementation in patients with congestive heart failure. J Am Coll Nutr 1997;16:22-31.
Gorelik O, Almoznino-Sarafian D, Feder I, Wachsman O, Alon I, Litvinjuk V, et al.
Dietary intake of various nutrients in older patients with congestive heart failure. Cardiology 2003;99:177-81.
Ceremuzyński L, Gebalska J, Wolk R, Makowska E. Hypomagnesemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation. J Intern Med 2000;247:78-86.
Adamopoulos C, Pitt B, Sui X, Love TE, Zannad F, Ahmed A, et al.
Low serum magnesium and cardiovascular mortality in chronic heart failure: A propensity-matched study. Int J Cardiol 2009;136:270-7.
Eichhorn EJ, Tandon PK, DiBianco R, Timmis GC, Fenster PE, Shannon J, et al.
Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: The PROMISE study. J Am Coll Cardiol 1993;21:634-40.
Fuentes JC, Salmon AA, Silver MA. Acute and chronic oral magnesium supplementation: Effects on endothelial function, exercise capacity, and quality of life in patients with symptomatic heart failure. Congest Heart Fail 2006;12:9-13.
Almoznino-Sarafian D, Berman S, Mor A, Shteinshnaider M, Gorelik O, Tzur I, et al.
Magnesium and C-reactive protein in heart failure: An anti-inflammatory effect of magnesium administration? Eur J Nutr 2007;46:230-7.
King DE, Mainous AG 3rd
, Geesey ME, Egan BM, Rehman S. Magnesium supplement intake and C- reactive protein levels in adults. Nutr Res 2006;26:193-6.
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1], [Table 2]